
<p style="text-align:start;hyphenate:none;font-family:Times New Roman;font-size:12pt;">
<span style="font-weight:bold;font-style:italic;text-decoration:underline;">PTEN</span><span style="font-weight:bold;text-decoration:underline;">-R130*-HNSC</span>
</p>

<p style="text-align:start;hyphenate:none;font-family:Times New Roman;font-size:12pt;">
<span style="font-weight:bold;font-style:italic;">Gene Function and clinical relevance</span><span style="font-weight:bold;">:</span><span style="font-family:Tahoma;font-size:9pt;font-weight:bold;"> </span><span style="color:black;">The </span><span style="font-style:italic;color:black;">PTEN</span><span style="color:black;"> gene encodes for the tumor suppressor protein, PTEN, which is a dual protein and lipid phosphatase. As a lipid phosphatase, it converts PIP3 to PIP2 and as a protein phosphatase; it dephosphorylates tyrosine, serine and threonine-phosphorylated proteins. The lipid phosphatase activity is critical for its function as a tumor suppressor protein as it inhibits the PI3K-AKT-mTOR signaling pathway. Somatic inactivating mutations and deletions in the </span><span style="font-style:italic;color:black;">PTEN</span><span style="color:black;"> gene are associated with multiple cancers including uterine (21%), prostate (19-22%), glioblastoma (32%), lung (2-4%) and breast (9-10%) cancers (TCGA, provisional, PMID:28481359)</span>
</p>

<p style="text-align:start;hyphenate:none;font-family:Times New Roman;font-size:12pt;">
<span style="font-weight:bold;font-style:italic;">Alteration and Frequency</span><span>: </span><span style="color:black;">The p.Arg130* (p.R130*) alteration in </span><span style="font-style:italic;color:black;">PTEN</span><span style="color:black;"> results in a premature truncation of the PTEN protein at amino acid 130 of 403, within the phosphatase tensin-type domain. The R130* results in loss of function of PTEN constitutes about 7% of </span><span style="font-style:italic;color:black;">PTEN</span><span style="color:black;"> altered head and neck cancers (PMID:28481359, TCGA, provisional).</span><span style="font-style:italic;color:black;"> PTEN </span><span style="color:black;">alterations are common in HPV-negative head and neck cancers (PMID:25631445).</span>
</p>

<p style="text-align:start;hyphenate:none;font-family:Times New Roman;font-size:12pt;">
<span style="font-weight:bold;font-style:italic;">Prognostic Implications</span><span>: Loss of Heterozygosity(LOH) on chromosome 10, in the </span><span style="font-style:italic;">PTEN</span><span> locus and loss of PTEN expression correlate with invasive and poorly differentiated carcinomas, lymph node metastases and poor prognosis of head and neck squamous cell carcinomas (PMID: 22413021).</span>
</p>

<p style="text-align:start;hyphenate:none;font-family:Times New Roman;font-size:12pt;">
<span style="font-weight:bold;font-style:italic;">Therapeutic Implications</span><span>: </span><span style="color:black;">There are no FDA approved or NCCN compendium recommended therapies selectively targeting </span><span style="font-style:italic;">PTEN </span><span>R130* alteration </span><span style="color:black;">in head and neck squamous cell carcinomas. </span>
</p>

<p style="text-align:start;hyphenate:none;font-family:Times New Roman;font-size:12pt;">
<span style="color:black;">In a phase II study, a head and neck squamous cell carcinoma patient with harboring a </span><span style="font-style:italic;color:black;">PTEN</span><span style="color:black;"> R130Q mutation exhibited a partial response on treatment with the combination of the mTOR inhibitor, </span><span style="font-weight:bold;color:black;">Temsirolimus</span><span style="color:black;">, </span><span style="font-weight:bold;color:black;">Carboplatin</span><span style="color:black;"> and </span><span style="font-weight:bold;color:black;">Paclitaxel</span><span style="color:black;"> (PMID: 28961834).</span>
</p>

<p style="text-align:start;hyphenate:none;font-family:Times New Roman;font-size:12pt;">
<span style="color:black;">In a preclinical study, </span><span style="font-style:italic;color:black;">PTEN</span><span style="color:black;"> mutant head and neck squamous cell carcinoma cell lines were less sensitive or resistant to inhibition by </span><span style="font-weight:bold;color:black;">Taselisib</span><span style="color:black;">, a PI3K-</span><span> α</span><span style="color:black;">, </span><span>δ</span><span style="color:black;">, </span><span>γ</span><span style="color:black;"> </span><a name="_GoBack"></a><a name="_GoBack"></a><span style="color:black;">isoform-specific inhibitor in a cell proliferation assay </span><span style="font-style:italic;color:black;">in vitro </span><span style="color:black;">(PMID: 26589432)</span>
</p>


